ストックスクリーナーアプリを入手
25.85
0.19%
0.05
アフターアワーズ：
25.88
0.03
+0.12%
Pfizer Inc (PFE) 最新ニュース
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next - ts2.tech
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks - ts2.tech
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - The Motley Fool
Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks
Orion Porfolio Solutions LLC Has $17.19 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025) - ts2.tech
Evergreen Capital Management LLC Purchases 63,611 Shares of Pfizer Inc. $PFE - MarketBeat
Forget Teladoc and Buy This Healthcare Stock Instead - Yahoo Finance
Bellevue Group AG Reduces Holdings in Pfizer Inc. $PFE - MarketBeat
Banque Transatlantique SA Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open - ts2.tech
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 - marketscreener.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 - Investing.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 By Investing.com - Investing.com Canada
Pfizer Declares First-Quarter 2026 Dividend - Business Wire
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. - The Globe and Mail
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring? - simplywall.st
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial - Reuters
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
CIBC Asset Management Inc Trims Stock Position in Pfizer Inc. $PFE - MarketBeat
Camber Capital Management LP Has $36.36 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. - Britannica
Elevance Health Adds Former Pfizer GC To Its Board - Law360
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield - ts2.tech
Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience - Healthcare Dive
Pfizer plans job cuts in Switzerland to reduce expenses - Yahoo Finance
Down 50%, should you buy the dip on Pfizer? - MSN
Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study - Finviz
Pfizer Inc. $PFE Shares Sold by Schwerin Boyle Capital Management Inc. - MarketBeat
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
Will Obesity Bet and TUKYSA Data Shift Pfizer’s (PFE) Post-COVID Growth Narrative? - simplywall.st
Pfizer Inc. $PFE Shares Sold by Marshall Wace LLP - MarketBeat
Pfizer Inc. $PFE Shares Sold by Becker Capital Management Inc. - MarketBeat
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating - Yahoo Finance
Pfizer Plans Workforce Reduction in Switzerland - marketscreener.com
Pfizer Could Claim Tukysa First-Line HER2+ Metastatic Breast Cancer Indication - Citeline News & Insights
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Pfizer to cut hundreds of jobs in Switzerland by year-end - Investing.com India
Pfizer stock gets Outperform rating from BMO as tucatinib shows promise - Investing.com
Former Pfizer physician challenges RIF, OWBPA disclosures in court - HRD America
Pfizer Plans to Cut 200+ Employees in Switzerland: Wire - AASTOCKS.com
Pfizer is shedding hundreds of jobs in Switzerland (PFE:NYSE) - Seeking Alpha
Pfizer to cut over 200 jobs in Switzerland to reduce costs, Bloomberg News reports - Reuters
Pfizer Inc. (PFE) announces results from the phase 3 BASIS study evaluating HYMPAVZI - MSN
Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI - Finviz
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports - marketscreener.com
Pfizer is cutting hundreds of jobs in Switzerland to lower costsBloomberg News - marketscreener.com
Pfizer Is Cutting Hundreds of Jobs in Switzerland to Lower Costs - Bloomberg.com
Expression Therapeutics Taps Former Pfizer, Novartis Exec as CEO - Contract Pharma
Pfizer’s tucatinib reduces disease progression risk in HER2+ breast cancer By Investing.com - Investing.com Australia
Pfizer Says Metatstatic Breast Cancer Treatment Extends Median Progression-Free Survival - marketscreener.com
PFIZER INC : JP Morgan remains Neutral - marketscreener.com
Pfizer’s tucatinib reduces disease progression risk in HER2+ breast cancer - Investing.com
Pfizer announces results from phase 3 HER2CLIMB-05 trial of Tukysa - marketscreener.com
Pfizer’s Tukysa Slows Breast Cancer When Added to First-Line Care - Bloomberg.com
Fosun's Yao Pharma, Pfizer sign exclusive collaboration dealVietnam Investment Review - Vietnam Investment Review - VIR
Intact Investment Management Inc. Has $16.21 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Lombard Odier Asset Management Switzerland SA - MarketBeat
HSBC Adjusts Price Target on Pfizer to $29 From $28, Maintains Buy Rating - marketscreener.com
China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer - Yahoo Finance
FDA investigating possible adult deaths from COVID-19 vaccines - The Lewiston Tribune
2.28%
0.11%
大文字化:
|
ボリューム (24 時間):